Literature DB >> 724583

The treatment of lupus nephritis by methyl prednisolone pulse therapy.

S Dosa, S A Cairns, W Lawler, N P Mallick, I N Slotki.   

Abstract

Four patients with proliferative glomerulonephritis due to systemic lupus erythematosus were treated with intravenous methyl prednisolone 'pulse' therapy. In all, eight courses of therapy were given, three for acute oliguric renal failure; and on each occasion there was a good response to the treatment. Clinical, histological and immunological details of the patients are presented. The diagnosis, treatment, and monitoring of disease activity in lupus nephritis are discussed in the light of this experience.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 724583      PMCID： PMC2425230          DOI： 10.1136/pgmj.54.635.628

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  21 in total

1.  Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody.

Authors:  J S Cameron; M H Lessof; C S Ogg; B D Williams; D G Williams
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

2.  The prognostic and therapeutic implications of DNA:anti-DNA immune complexes in systemic lupus erythematosus (SLE).

Authors:  E J Bardana; R J Harbeck; A A Hoffman; B Pirofsky; R I Carr
Journal:  Am J Med       Date:  1975-10       Impact factor: 4.965

3.  CLINICAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. COMPUTER ANALYSIS OF 520 CASES.

Authors:  E L DUBOIS; D L TUFFANELLI
Journal:  JAMA       Date:  1964-10-12       Impact factor: 56.272

4.  Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis.

Authors:  V E POLLAK; C L PIRANI; R M KARK
Journal:  J Lab Clin Med       Date:  1961-04

5.  Acute renal failure in systemic lupus erythematosus.

Authors:  C Ponticelli; E Imbasciati; D Brancaccio; A Tarantino; E Rivolta
Journal:  Br Med J       Date:  1974-09-21

6.  Serum immune complexes and disease activity in lupus nephritis.

Authors:  R J Levinsky; J S Cameron; J F Soothill
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

7.  The clinical course of the proliferative and membranous forms of lupus nephritis.

Authors:  D S Baldwin; J Lowenstein; N F Rothfield; G Gallo; R T McCluskey
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

8.  Lupus nephritis. Renal function after prolonged survival.

Authors:  N E Gary; J F Maher; G E Schreiner
Journal:  N Engl J Med       Date:  1967-01-12       Impact factor: 91.245

9.  The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients.

Authors:  B H Bulkley; W C Roberts
Journal:  Am J Med       Date:  1975-02       Impact factor: 4.965

10.  Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy.

Authors:  G C Sharp; W S Irvin; R L LaRoque; C Velez; V Daly; A D Kaiser; H R Holman
Journal:  J Clin Invest       Date:  1971-02       Impact factor: 14.808
View more
  11 in total

1.  Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.

Authors:  Oliver Lenz; Alessia Fornoni; Gabriel Contreras
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Pulsed methylprednisolone.

Authors:  A Oto; T Sozen; S Boyacioglu
Journal:  Ann Rheum Dis       Date:  1981-12       Impact factor: 19.103

3.  The value of three immune complex assays in the management of systemic lupus erythematosus: an assessment of immune complex levels, size and immunochemical properties in relation to disease activity and manifestations.

Authors:  S A Cairns; A London; N P Mallick
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

4.  A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment.

Authors:  J C Edwards; M L Snaith; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

Review 5.  Current treatment recommendations for lupus nephritis.

Authors:  C Ponticelli
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 6.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

7.  The delayed appearance of an antinuclear factor and the diagnosis of systemic lupus erythematosus in glomerulonephritis.

Authors:  S A Cairns; E J Acheson; C L Corbett; S Dosa; N P Mallick; W Lawler; G Williams
Journal:  Postgrad Med J       Date:  1979-10       Impact factor: 2.401

Review 8.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Mechanism by which methylprednisolone inhibits acute immune complex-induced changes in vascular permeability.

Authors:  K R McLeish; F N Miller; G T Stelzer; S R Wellhausen
Journal:  Inflammation       Date:  1986-09       Impact factor: 4.092

10.  Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus.

Authors:  D A Isenberg; W J Morrow; M L Snaith
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.